Troy C Lund1, Terence M Doherty2, Julie B Eisengart1, Rebecca L Freese3, Kyle D Rudser4, Ellen B Fung5, Bradley S Miller1, Klane K White6, Paul J Orchard1, Chester B Whitley1, Lynda E Polgreen2. 1. Department of Pediatrics University of Minnesota Minneapolis Minnesota USA. 2. Department of Pediatrics The Lundquist Institute at Harbor-UCLA Medical Center Torrance California USA. 3. Biostatistical Design and Analysis Center, Clinical and Translational Science Institute University of Minnesota Minneapolis Minnesota USA. 4. School of Public Health, Division of Biostatistics University of Minnesota Minneapolis Minnesota USA. 5. Department of Hematology University of California, San Francisco Benioff Children's Hospital Oakland California USA. 6. Department of Orthopaedics and Sports Medicine Seattle Children's Hospital Seattle Washington USA.
Abstract
BACKGROUND: Orthopedic disease progresses in mucopolysaccharidosis type I (MPS I), even with approved therapies and remains a major factor in persistent suffering and disability. Novel therapies and accurate predictors of response are needed. The primary objective of this study was to identify surrogate biomarkers of future change in orthopedic disease. METHODS: As part of a 9-year observational study of MPS I, range-of-motion (ROM), height, pelvic radiographs were measured annually. Biomarkers in year 1 were compared to healthy controls. Linear regression tested for associations of change in biomarkers over the first year with change in long-term outcomes. RESULTS: MPS I participants (N = 19) were age 5 to 16 years and on average 6.9 ± 2.9 years post treatment initiation. Healthy controls (N = 51) were age 9 to 17 years. Plasma IL-1β, TNF-α, osteocalcin, pyridinolines, and deoxypyridinolines were higher in MPS than controls. Within MPS, progression of hip dysplasia was present in 46% to 77%. A 1 pg/mL increase in IL-6 was associated with -22°/year change in ROM (-28 to -15; P < .001), a 20 nmol/mmol creatinine/year increase in urine PYD was associated with a -0.024 Z-score/year change in height Z-score (-0.043 to -0.005; P = .016), and a 20 nmol/mmol creatinine/year increase in urine PYD was associated with a -2.0%/year change in hip dysplasia measured by Reimers migration index (-3.8 to -0.1; P = .037). CONCLUSIONS: Inflammatory cytokines are high in MPS I. IL-6 and PYD were associated with progression in joint contracture, short stature, and hip dysplasia over time. Once validated, these biomarkers may prove useful for predicting response to treatment of skeletal disease in MPS I.
BACKGROUND: Orthopedic disease progresses in mucopolysaccharidosis type I (MPS I), even with approved therapies and remains a major factor in persistent suffering and disability. Novel therapies and accurate predictors of response are needed. The primary objective of this study was to identify surrogate biomarkers of future change in orthopedic disease. METHODS: As part of a 9-year observational study of MPS I, range-of-motion (ROM), height, pelvic radiographs were measured annually. Biomarkers in year 1 were compared to healthy controls. Linear regression tested for associations of change in biomarkers over the first year with change in long-term outcomes. RESULTS: MPS I participants (N = 19) were age 5 to 16 years and on average 6.9 ± 2.9 years post treatment initiation. Healthy controls (N = 51) were age 9 to 17 years. Plasma IL-1β, TNF-α, osteocalcin, pyridinolines, and deoxypyridinolines were higher in MPS than controls. Within MPS, progression of hip dysplasia was present in 46% to 77%. A 1 pg/mL increase in IL-6 was associated with -22°/year change in ROM (-28 to -15; P < .001), a 20 nmol/mmol creatinine/year increase in urine PYD was associated with a -0.024 Z-score/year change in height Z-score (-0.043 to -0.005; P = .016), and a 20 nmol/mmol creatinine/year increase in urine PYD was associated with a -2.0%/year change in hip dysplasia measured by Reimers migration index (-3.8 to -0.1; P = .037). CONCLUSIONS: Inflammatory cytokines are high in MPS I. IL-6 and PYD were associated with progression in joint contracture, short stature, and hip dysplasia over time. Once validated, these biomarkers may prove useful for predicting response to treatment of skeletal disease in MPS I.
Authors: Eveline J Langereis; Naomi van Vlies; Heather J Church; Ronald B Geskus; Carla E M Hollak; Simon A Jones; Wim Kulik; Henk van Lenthe; Jean Mercer; Lena Schreider; Karen L Tylee; Tom Wagemans; Frits A Wijburg; Brian W Bigger Journal: Mol Genet Metab Date: 2014-10-29 Impact factor: 4.797
Authors: C B Whitley; K G Belani; P N Chang; C G Summers; B R Blazar; M Y Tsai; R E Latchaw; N K Ramsay; J H Kersey Journal: Am J Med Genet Date: 1993-04-15
Authors: David A Stevenson; Kyle Rudser; Alicia Kunin-Batson; Ellen B Fung; David Viskochil; Elsa Shapiro; Paul J Orchard; Chester B Whitley; Lynda E Polgreen Journal: J Pediatr Rehabil Med Date: 2014
Authors: Calogera M Simonaro; Marina D'Angelo; Xingxuan He; Efrat Eliyahu; Nataly Shtraizent; Mark E Haskins; Edward H Schuchman Journal: Am J Pathol Date: 2007-12-13 Impact factor: 4.307
Authors: Eveline J Langereis; Matthijs M den Os; Catherine Breen; Simon A Jones; Olga C Knaven; Jean Mercer; Weston P Miller; Paula M Kelly; Jim Kennedy; Tyler G Ketterl; Anne O'Meara; Paul J Orchard; Troy C Lund; Rick R van Rijn; Ralph J Sakkers; Klane K White; Frits A Wijburg Journal: J Bone Joint Surg Am Date: 2016-03-02 Impact factor: 5.284
Authors: Gerald V Raymond; Marzia Pasquali; Lynda E Polgreen; Patricia I Dickson; Weston P Miller; Paul J Orchard; Troy C Lund Journal: Sci Rep Date: 2016-12-02 Impact factor: 4.379
Authors: Julie B Eisengart; Kyle D Rudser; Yong Xue; Paul Orchard; Weston Miller; Troy Lund; Ans Van der Ploeg; Jean Mercer; Simon Jones; Karl Eugen Mengel; Seyfullah Gökce; Nathalie Guffon; Roberto Giugliani; Carolina F M de Souza; Elsa G Shapiro; Chester B Whitley Journal: Genet Med Date: 2018-03-08 Impact factor: 8.822
Authors: Karolina M Stepien; Andrew Bentley; Cliff Chen; M Wahab Dhemech; Edward Gee; Peter Orton; Catherine Pringle; Jonathan Rajan; Ankur Saxena; Govind Tol; Chaitanya Gadepalli Journal: Front Cardiovasc Med Date: 2022-03-07